Halle Tecco, cofounder of Rock Health and a prolific investor in the healthcare space, is stepping back from her prominent role in fertility care after a decade of advocacy and entrepreneurship. Tecco has long been a leading voice for improved fertility care, founding fertility-focused ventures like Natalist in 2019 and Cofertility in 2022. However, despite her success in launching companies aimed at empowering individuals with better fertility options, Tecco’s personal battles with infertility continued to unfold behind the scenes.
Tecco, who suffered through eleven miscarriages, including the heartbreaking loss of twins at 17 weeks, is now closing this chapter of her life. In a recent interview, she revealed her decision to move away from fertility care and its associated challenges. “I’m not trying to be an infertility influencer,” she told Business Insider. After years of navigating her own painful journey while also supporting others in their struggles to conceive, Tecco decided it was time to step away from the narrative that had come to define her in the public eye.
As a successful entrepreneur and early investor in fertility startups, Tecco played a key role in transforming the landscape of women’s health. From founding Natalist, which offers products and educational materials for those trying to conceive, to backing early-stage companies like Kindbody, Tecco was at the forefront of the femtech boom. However, her own fertility journey—marked by multiple failed IVF attempts and a relentless battle with secondary infertility—eventually led to emotional and physical exhaustion.
“I wanted to go into my 40s being really clear about my intentions of moving on,” she shared, reflecting on her decision to focus on her family rather than pursue additional fertility treatments. After much personal reflection and therapy, Tecco made peace with her decision not to pursue further treatment, instead prioritizing her well-being and family life.
Today, Tecco is shifting her focus to the broader healthcare sector. No longer making new fertility-related investments, she is returning to her roots in digital health innovation. Tecco’s passion for healthcare technology dates back to her time at Harvard Business School, where she began exploring how to bring fresh, entrepreneurial ideas to the often sluggish healthcare industry. This led her to cofound Rock Health in 2010, an accelerator program designed to help healthcare startups navigate the complex landscape of the sector. Through Rock Health, Tecco and her cofounder Nate Gross supported a wide range of healthcare innovations, with investments in companies like Waystar, Tempus AI, and Omada Health, among others.
In addition to her work with Rock Health, Tecco is now writing a book about healthcare innovation, teaching a course at Harvard Medical School, and co-hosting the podcast The Heart of Healthcare. She is also focusing on her role as a board member at Cofertility, where she continues to provide strategic guidance while stepping back from daily operations. Despite stepping away from angel investing, Tecco is still involved with her existing investments and continues to support healthcare startups through established venture funds.
While Tecco is no longer focused on fertility care, she remains committed to her vision of transforming healthcare through innovation. “My goal is that readers close the book and they’re like, let’s do this,” she said, reflecting her belief in the potential to make impactful changes in healthcare.
Her shift away from the fertility space does not diminish her commitment to improving women’s health. Though no longer a patient in the fertility system, Tecco’s experiences and advocacy have helped shine a light on the financial and emotional challenges faced by individuals navigating assisted reproduction. However, her personal story has evolved, and with it, her professional journey as she looks to broader horizons in the healthcare sector.
Related topics:
Alex Drummond Shares Pregnancy Update as She Prepares for Her First Child
Heranova Launches HerResolve™: A Breakthrough Blood Test for Early Endometriosis Diagnosis with 92% Accuracy
